Abdelmalek Ossaden

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
INTRODUCTION Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors. Although the response rate in patients treated with imatinib mesylate in prospective clinical studies is above 50%, a complete response is(More)
  • 1